Business · 04/12/2018Updated: 10/17/2026 · 1 min read
FDA Releases Draft Guidance for Nonalcoholic Steatohepatitis Treatment
Summary
The FDA has published a draft guidance to help pharmaceutical companies develop drugs for treating nonalcoholic steatohepatitis with liver fibrosis, a condition affecting the liver.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →